Ocular Therapeutix, Inc.
$9.52
▲
1.92%
2026-04-21 08:35:01
www.ocutx.com
NGM: OCUL
Explore Ocular Therapeutix, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$2.09 B
Current Price
$9.52
52W High / Low
$16.44 / $6.23
Stock P/E
—
Book Value
$3.03
Dividend Yield
—
ROCE
-35.66%
ROE
-54.85%
Face Value
—
EPS
$-1.42
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
325
Beta
0.95
Debt / Equity
11.76
Current Ratio
15.39
Quick Ratio
15.32
Forward P/E
-7
Price / Sales
36.83
Enterprise Value
$1.25 B
EV / EBITDA
-4.72
EV / Revenue
24.13
Rating
Strong Buy
Target Price
$26
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | PolyPid Ltd. | $4.69 | — | $89.5 M | — | -226.3% | -3.66% | $5.12 / $2.44 | $0.6 |
| 2. | Imunon, Inc. | $3.1 | — | $12.36 M | — | -191.16% | -2.56% | $41.22 / $2.52 | $2.42 |
| 3. | Unicycive Therapeutics, Inc. | $7.43 | — | $177.17 M | — | -97.75% | -1.41% | $11 / $3.71 | $1.36 |
| 4. | Arcus Biosciences, Inc. | $22.74 | — | $2.85 B | — | -42.51% | -63.26% | $26.4 / $7.06 | $5.04 |
| 5. | enGene Therapeutics Inc. | $8.53 | — | $571.42 M | — | -65% | -46.07% | $12.25 / $2.65 | $4.2 |
| 6. | Curanex Pharmaceuticals Inc | $0.48 | — | $12.79 M | — | -37.04% | -85.25% | $9.18 / $0.26 | $0.01 |
| 7. | Skye Bioscience, Inc. | $0.78 | — | $26.15 M | — | -289.25% | -1.27% | $5.75 / $0.57 | $0.6 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 13.25 M | 14.54 M | 13.46 M | 10.7 M | 17.08 M |
| Operating Profit | -69.76 M | -68.7 M | -67.64 M | -63.92 M | -50.58 M |
| Net Profit | -64.65 M | -69.42 M | -67.81 M | -64.05 M | -48.39 M |
| EPS in Rs | -0.3 | -0.32 | -0.31 | -0.29 | -0.22 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 51.95 M | 63.72 M | 58.44 M | 51.49 M |
| Operating Profit | -270.02 M | -171.78 M | -82.38 M | -78.65 M |
| Net Profit | -265.94 M | -193.51 M | -80.74 M | -71.04 M |
| EPS in Rs | -1.22 | -0.89 | -0.37 | -0.33 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 808.06 M | 457.94 M | 252.06 M | 149.29 M |
| Total Liabilities | 153.75 M | 142.59 M | 160.93 M | 113.91 M |
| Equity | 654.31 M | 315.34 M | 91.13 M | 35.38 M |
| Current Assets | 782.13 M | 440.99 M | 232.24 M | 129.63 M |
| Current Liabilities | 50.81 M | 41.35 M | 34.9 M | 31.39 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -204.88 M | -134.68 M | -70.23 M | -59.6 M |
| Investing CF | -11.88 M | -1.29 M | -6.09 M | -3.71 M |
| Financing CF | 561.72 M | 332.11 M | 169.83 M | 1.45 M |
| Free CF | -216.89 M | -135.97 M | -76.32 M | -63.32 M |
| Capex | -12.01 M | -1.29 M | -6.09 M | -3.71 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 9.03% | 13.49% | — | — |
| Earnings Growth % | -139.68% | -13.65% | — | — |
| Profit Margin % | -303.67% | -138.14% | -137.95% | — |
| Operating Margin % | -269.57% | -140.96% | -152.74% | — |
| Gross Margin % | 91.17% | 90.96% | 91.18% | — |
| EBITDA Margin % | -276.42% | -113.64% | -120.22% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.